These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34702746)

  • 21. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
    Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T
    Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.
    Tseng JH; Cowan RA; Afonso AM; Zhou Q; Iasonos A; Ali N; Thompson E; Sonoda Y; O'Cearbhaill RE; Chi DS; Abu-Rustum NR; Long Roche K
    Gynecol Oncol; 2018 Nov; 151(2):287-293. PubMed ID: 30185381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).
    Fagotti A; Ferrandina MG; Vizzielli G; Pasciuto T; Fanfani F; Gallotta V; Margariti PA; Chiantera V; Costantini B; Gueli Alletti S; Cosentino F; Scambia G
    Int J Gynecol Cancer; 2020 Nov; 30(11):1657-1664. PubMed ID: 33028623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
    Tseng JH; Cowan RA; Zhou Q; Iasonos A; Byrne M; Polcino T; Polen-De C; Gardner GJ; Sonoda Y; Zivanovic O; Abu-Rustum NR; Long Roche K; Chi DS
    Gynecol Oncol; 2018 Oct; 151(1):24-31. PubMed ID: 30126704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
    Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.
    Suidan RS; Ramirez PT; Sarasohn DM; Teitcher JB; Iyer RB; Zhou Q; Iasonos A; Denesopolis J; Zivanovic O; Long Roche KC; Sonoda Y; Coleman RL; Abu-Rustum NR; Hricak H; Chi DS
    Gynecol Oncol; 2017 Apr; 145(1):27-31. PubMed ID: 28209497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Surgery for advanced stage ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
    Ferron G; Narducci F; Pouget N; Touboul C
    Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):197-213. PubMed ID: 30792175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
    Manning-Geist BL; Chi DS; Long Roche K; Zivanovic O; Sonoda Y; Gardner GJ; O'Cearbhaill RE; Abu-Rustum NR; Leitao MM
    Gynecol Oncol; 2021 Aug; 162(2):345-352. PubMed ID: 34045053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between BMI and oncologic outcomes in epithelial ovarian cancer: a predictors-matched case-control study.
    Levin G; Brezinov Y; Tzur Y; Bar-Noy T; Brodeur MN; Salvador S; Lau S; Gotlieb W
    Arch Gynecol Obstet; 2024 Jul; 310(1):587-593. PubMed ID: 38714562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncologic outcomes of uterine preservation for pre-menopausal patients with stage II epithelial ovarian carcinoma.
    Nasioudis D; Mulugeta-Gordon L; McMinn E; Byrne M; Ko EM; Cory L; Haggerty AF; Latif NA
    Int J Gynecol Cancer; 2021 Mar; 31(3):480-483. PubMed ID: 33649017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study.
    Szender JB; Emmons T; Belliotti S; Dickson D; Khan A; Morrell K; Khan ANMN; Singel KL; Mayor PC; Moysich KB; Odunsi K; Segal BH; Eng KH
    Gynecol Oncol; 2017 Sep; 146(3):491-497. PubMed ID: 28624153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
    Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
    J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival outcomes of epithelial ovarian cancer treated at a tertiary-level hospital in India.
    Chandy RG; Thomas V; Sebastian A; Mani T; Thomas A; Joel A; Ram TS; Peedicayil A
    Indian J Cancer; 2023 Oct; 60(4):475-485. PubMed ID: 38185864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data.
    Irodi A; Rye T; Herbert K; Churchman M; Bartos C; Mackean M; Nussey F; Herrington CS; Gourley C; Hollis RL
    BJOG; 2020 Oct; 127(11):1409-1420. PubMed ID: 32285600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer.
    Luger AK; Steinkohl F; Aigner F; Jaschke W; Marth C; Zeimet AG; Reimer D
    Acta Obstet Gynecol Scand; 2020 Aug; 99(8):1092-1099. PubMed ID: 32112653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer.
    Angeles MA; Ferron G; Cabarrou B; Balague G; Martínez-Gómez C; Gladieff L; Pomel C; Martinez A
    Eur J Surg Oncol; 2019 Aug; 45(8):1410-1416. PubMed ID: 30857876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery.
    Sørensen SM; Schnack TH; Høgdall C
    Acta Obstet Gynecol Scand; 2019 Jan; 98(1):34-43. PubMed ID: 30168853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.
    van Vliet MM; Schreuder HW; Pasker-de Jong PC; Duk MJ
    Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():72-8. PubMed ID: 26177496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.